Abstract. Chemotherapeutic agents are active in advanced bladder cancer, and various combinations have shown promising results. The objective of this study was to evaluate the efficacy of combination chemotherapy with gemcitabine, paclitaxel, and cisplatin in patients with advanced urothelial carcinoma. Fifty-nine patients with metastatic or locally advanced transitional cell carcinoma of the urothelium were treated between 2000 and 2005. No patient had received any previous systemic chemotherapy. All patients received chemotherapy intravenously with gemcitabine at a dose of 1000 mg/m² on days 1 and 8, paclitaxel at a dose of 80 mg/m² on days 1 and 8, and cisplatin at a dose of 50 mg/m² on day 2. Treatment courses were repeated every 21 days. After completion of four to six courses in this regimen an intravenous application of gemcitabine was repeated every 28 days at a dose of 1000 mg/m². Fifty-nine patients were treated between 2000 and 2005. Nine patients (15%) had ≥1 visceral site of metastases, and no patient had received any previous systemic chemotherapy. Forty-eight patients (81%) achieved objective responses to treatment (56% complete responses). The median actuarial survival was 22 months, and the actuarial 1-year and 2-year survival rates were 68% and 39%, respectively. After a median follow-up of 17.5 months, 29 patients remained alive and 25 were free of disease progression. The median progression-free survival for the entire group was 10 months. The median survival time for patients with an Eastern Cooperative Oncology Group (ECOG) status of 0, 1, and 2 was 37.5, 17, and 12 months, respectively. Grade 3-4 neutropenia occurred in 39% of the patients. The combination of gemcitabine, paclitaxel, and cisplatin is a highly effective and tolerable regimen for patients with advanced urothelial carcinoma. This treatment should be considered as a suitable option that deserves further prospective evaluation. The ECOG performance status is an important predictive factor for survival.

Introduction

Transitional cell carcinoma (TCC) of the urothelium has a high prevalence among the elderly. Approximately 80% of those who are affected are between 50-79 years of age (1). When diagnosed, 20-30% of bladder carcinomas display muscle infiltration, and 50% of these metastasize (2-4). The prognosis for metastasized urothelial carcinomas is poor and the average survival rate for untreated patients is 3-6 months (5).

Advanced transitional cell carcinoma of the urothelium is moderately sensitive to chemotherapy, and there are a number of agents that produce response rates in the 10-40% range (6-8). Cisplatin is one of the most effective single-agent treatments for metastatic urothelial cancer, and forms the cornerstone of combination chemotherapy. In the 1980s the chemosensitivity of urothelial cell cancer was recognized when phase II studies demonstrated the activity of cisplatin, methotrexate, adriamycin, vinblastine and 5FU in advanced and/or metastatic disease. The next step in developing a more effective therapy was to combine these known effective agents into two-, three-, and four-drug combinations (9). In 1985 investigators from the Memorial Sloan Kettering Cancer Center reported a four-drug regimen of cisplatin, doxorubicin, methotrexate and vinblastine (MVAC) (10). The initial study on 24 patients gave an overall response rate of 71%. In an updated report on a larger series of 121 evaluable patients, the overall response rate to MVAC was 72%, with a clinical complete response rate to chemotherapy alone of 18% and with an additional 11% of the patients being rendered disease free with post chemotherapy surgery (11). Unfortunately, MVAC therapy is associated with significant morbidity. Also the prognosis of patients with metastatic transitional cell carcinoma remains poor, with a median survival of only 12-14 months (6,11-13). Furthermore, the MVAC regimen is relatively toxic, and it is difficult to administer to elderly patients and to patients who have a poor performance status.

In the past decade, several new chemotherapeutic agents have shown activity against advanced urothelial bladder
cancer, including the taxanes paclitaxel and docetaxel (14-18), and gemcitabine (19-22). Gemcitabine (Gemzar®, Eli Lilly & Co., Indianapolis, IN, USA) is a pyrimidine antimetabolite that has preclinical and clinical activity against urothelial cancer with an overall response rate of 30% in previously treated and untreated patients (19,23). Gemcitabine offers proven activity against a range of solid tumors (20.24-26).

In particular, in metastatic urothelial cancer, gemcitabine alone yielded response rates of 23-29% with a complete response rate of 4-13%, in both previously treated and untreated patients (5). The good activity and toxicity profile of single-agent gemcitabine and its synergism with cisplatin in pre-clinical models (27) have led to the development of this combination in advanced TCC. Von der Maase et al (13) reported on a large multinational phase III trial comparing the M-VAC regimen with gemcitabine plus cisplatin (GC), with a total of 405 patients accrued. The final results showed that the two regimens were similar in terms of response rate, time to progression and survival. However, the GC combination provided a better safety profile with decreased toxicity. Based on these data, the GC combination proved to be a standard alternative treatment in patients with advanced TCC.

Paclitaxel (Taxol®) is an anti-microtubule agent that stabilizes microtubules, induces G2/M cell cycle arrest, as well as the phosphorylation of the anti-apoptotic protein bcl-2 (28), and has preclinical and clinical activity against TCC (16,29). Initial phase II studies of two-drug combinations of docetaxel, or paclitaxel, with cisplatin, have shown activity in untreated patients, with response rates that are in the same range as obtained with MVAC (30-35).

In view of the activity of gemcitabine and the taxanes, the partially non-overlapping toxicities of these agents and their different mechanisms of action, the next logical step was to combine these compounds, and incorporate platinum as the back-bone in a three-drug regimen. Investigators in Spain conducted phase I/II trials of the triplet combination of paclitaxel, cisplatin, and gemcitabine (PCG) in a total of 61 patients (36). The investigators began their study in a formal phase I setting, escalating the dose levels of both paclitaxel and gemcitabine, administered weekly, on days 1 and 8, with a fixed dose of 70 mg/m² cisplatin, on day 1, every three weeks. At dose level 4, with paclitaxel at 90 mg/m² weekly, grade 3 asthenia was determined to be the dose-limiting toxicity. With this schedule and dose intensity, asthenia, as well as myelotoxicity were manageable. G-CSF was used only for secondary prophylaxis in patients in whom either neutropenic fever or grade 4 neutropenia had been observed in the preceding cycle. The phase I study (15 patients) and phase II study (46 evaluable patients) together gave an overall response rate of 78% and a median survival time for the phase I and the phase II part of the study of 24 and 16 months, respectively. In view of these results, several international groups of oncology have begun the largest randomized trial ever designed in metastatic bladder cancer to compare the three-drug design regimen of PCG with the two-drug combination of GC. A total of 610 patients will be needed to detect a difference in survival of 4 months (from 14 to 18 months). The study is restricted to patients with a good clinical performance status [an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1] and a creatinine clearance of at least 60 ml/min.

Since information about the predictive factors for response and survival is needed for the selection of patients who are likely to benefit from new combinations and for stratification purposes in randomized trials, an analysis of the predictive factors for response and survival with the regimen containing PCG was performed (37). The pretreatment characteristics analyzed were age, gender, ECOG performance status (38), histopathology, visceral metastasis (bone, liver, lung), number of sites of disease, LDH and hemoglobin. The factors that were associated with decreased survival in the univariate analysis were a performance status of >0, the presence of visceral metastasis, and more than one site of malignant disease.

In our study we also included patients with an ECOG status of 2 and a lower creatinine clearance with the application of a reduced dose. This nonrandomized retrospective study was designed to evaluate the feasibility, toxicity, and efficacy of this three-drug chemotherapy regimen in patients with advanced urothelial carcinoma. Previous experience with either gemcitabine plus platinum regimens had produced response rates of 41-56%, with median survivals in the range of 10-14 months. Therefore, the achievement of a response rate of >60% or a median survival of >14 months with this regimen would be indicative of sufficient activity to proceed with further development (39).

Patients and methods

Eligibility. Patients who were eligible for this trial were required to have histologically confirmed transitional cell carcinoma of the urothelial tract (bladder, ureter, or renal pelvis) that was either metastatic or locally advanced and unresectable. Patients with locally advanced, unresectable bladder carcinoma who had any possibility of curative therapy with combined-modality treatment were excluded from this trial. All patients were required to have measurable disease. Patients were not allowed to have received a previous systemic chemotheray regimen. Previous intravesical treatment was allowed if the most recent intravesical therapy was completed >1 month prior to the study enrolment. Previous radiation therapy was not allowed.

Additional eligibility requirements included the following: An ECOG performance status of 0 to 2, a leukocyte count of ≥3,000/μl, a platelet count of ≥100,000/μl, serum bilirubin <1.5 mg/dl, serum creatinine ≥2.5 mg/dl, and age >18 years. Patients with other active malignancies or with any other serious or active medical conditions were excluded. Pregnant or lactating females were ineligible. All patients were required to provide written informed consent prior to the study enrolment.

Pretreatment evaluation. Prior to enrolling in this trial, all patients were required to have a complete history, physical examination, complete blood counts, differential, chemistry profile, and urinalysis. In addition, patients underwent computed tomography scans of the chest, abdomen, and pelvis with appropriate tumor measurements.

Treatment. All patients received treatment with the following regimen: Gemcitabine at a dose of 1,000 mg/m² as a 30-min
intravenous infusion followed by paclitaxel at a dose of 80 mg/m² as a 1-h intravenous infusion on days 1 and 8. On day 2 cisplatin was applied at a dose of 50 mg/m² as an intravenous infusion and hydration with 2,000 ml NaCl 0.9%. The regimen was repeated every 21 days. Patients received standard paclitaxel premedication and antiemetic prophylaxis.

After completion of four to six courses in this regimen a further therapy followed: Gemcitabine at a dose of 1,000 mg/m² as a 30-min intravenous infusion. The regimen was repeated every 28 days.

For the patients who had rapid progress after completing the three-drug regimen with gemcitabine, paclitaxel, and cisplatin or during gemcitabine monotherapy, we used the common three-drug chemotherapy with methotrexate, epirubicine, and cisplatin. The regimen of the courses was as follows: Methotrexate at a dose of 30 mg/m² as a very short intravenous infusion on days 1 and 15. On day 2 cisplatin was applied at a dose of 70 mg/m² as an intravenous infusion and hydration with 2,000 ml NaCl 0.9% followed by epirubicine at a dose of 30 mg/m² as a short intravenous infusion. The regimen was repeated every 21 days. Patients received standard premedication and anti-emetic prophylaxis.

**Dose modifications.** All patients received full doses of all 3 agents on day 1 of the first course of treatment. Subsequent doses were based on the hematological and nonhematological toxicity observed. Dose modifications for myelosuppression were determined by the blood counts measured on the day of scheduled treatment. Nadir blood counts were not used as a basis for dose reduction.

On day 1 of each course, full doses of all drugs were administered if the leukocyte count was ≥3,000/μl and the platelet count was >100,000/μl. If the leukocyte count was ≤3,000/μl or the platelet count was <100,000/μl, then treatment was delayed for one or two days.

All patients with an ECOG performance status of 2, or with renal insufficiency in the stage of compensated retention received reduced doses of 50% to 70%. In the case of good tolerance of the therapy we applied higher doses for the following cycles.

**Assessment of treatment efficacy.** Patients were evaluated for response to treatment after the completion of 4 courses (12 weeks). Re-evaluation included a repeat of all previously abnormal radiological studies with a repeat of objective tumor measurement. Patients who achieved an objective response (complete or partial) or stable disease after the completion of four courses of therapy continued treatment with this regimen. Re-evaluations were performed after the completion of each additional courses of therapy. Treatment was continued for a total of 6 courses. Patients who completed 6 courses and remained in remission were given further treatment with a single dose of gemcitabine. This additional treatment was continued for at least two years. Patients who completed these two years of gemcitabine monotherapy and remained in remission did not receive any further specific treatment and were re-evaluated for ongoing response at 3-month intervals including a clinical examination, ultrasound of the abdomen and computed tomography scans of the chest, abdomen, and pelvis with appropriate tumor measurements.

Table I. Histological staging and grading of patients.

<table>
<thead>
<tr>
<th>Staging/grading</th>
<th>G1</th>
<th>G2</th>
<th>G3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>T2</td>
<td>1</td>
<td>3</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>T3-4</td>
<td>0</td>
<td>6</td>
<td>26</td>
<td>32</td>
</tr>
<tr>
<td>T4</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>2</td>
<td>10</td>
<td>47</td>
<td>59</td>
</tr>
</tbody>
</table>

**Response definitions.** Responses were defined using the World Health Organization Response criteria. A complete response required the total disappearance of all clinically and radiographically detected tumors for at least 4 weeks. Patients had partial response if treatment produced a reduction of ≥50% in the size of measurable lesions, as measured by the product of the greatest perpendicular dimensions, with no evidence of new disease if measurable lesions were reduced by <50% or increased by <25%, as determined by the measurement of the products of the greatest perpendicular dimensions, with no new lesions appearing. Patients who had any appearance of new lesions or who had an increase of >25% in the size of any existing lesions had progressive disease.

Progression-free survival was defined as the interval between the date of the first treatment and the date of documented tumor progression.

**Statistical analysis.** Survival was measured from the time of the initiation of chemotherapy until death or the last follow-up. Actuarial survival curves were constructed using the Kaplan-Meier method (40). Statistical analysis included the Chi-square test after Pearson’s correlation was computed and performed by the computer program SPSS 12.0.1. All patients who received at least two doses of treatment were included in the toxicity analysis. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria.

**Results**

**Patient population.** From August 2000 to November 2005 a total of 59 patients were included in the trial. Forty-five male patients and 14 female patients (average age 69.7 years, median age 70 years) were included. The pathohistological stage and grade is shown in Table I. The patient characteristics are summarized in Table II. The majority of patients (35 out of 59 patients = 59%) had metastatic disease. Four patients (7%) were treated with radical tumor surgery and came to progress (lymph node or visceral metastases) >1 year after the first treatment. Twenty-seven patients (46%) had lymph node or visceral metastases just after radical tumor surgery. Six (10%) patients had lymph node or visceral metastases before surgery and no surgical treatment was done before chemotherapy. Nineteen patients (32%) had neither lymph node nor visceral metastases just after radical tumor surgery. Three (5%) patients had neither lymph node nor visceral...
metastases before surgery and no surgical treatment was done before chemotherapy because of non-compliance for surgical therapy. In summary, we included 24 patients (41%) with advanced urothelial cancer without lymph node or visceral metastases, 26 patients (44%) had advanced urothelial cancer and lymph node metastases without visceral metastases, and 9 patients (15%) had advanced urothelial cancer and visceral metastases (Table II). The ECOG performance status at the point of starting chemotherapy was 0 for 24 patients (41%), 1 for 26 patients (44%), and 2 for 9 patients (15%). Before the beginning of chemotherapy 48 patients (81%) had radical tumor surgery: Radical cystectomy or nephroureterectomy. No patient had received previous chemotherapy or radiation.

**Treatment schedule.** All 59 patients received at least two courses of treatment and were evaluated for response. Thirty-four patients received gemcitabine monotherapy. Five patients received the second line chemotherapy (MEC) because of rapid progression after the three-drug regimen with gemcitabine, paclitaxel, and cisplatin or during gemcitabine monotherapy.

The median number of treatment courses received in the first line three-drug regimen with gemcitabine, paclitaxel, and cisplatin was five (range, two to seven courses). A reduced dose of the three drugs was administered to 38 patients (64%). This high number of reduced doses given is because 25 patients (42%) had an ECOG performance score of 1, and 10 patients (17%) had an ECOG performance score of 2. Therefore, the large majority of dose modifications in this clinical trial were on the basis of a bad performance score and parallel diseases such as renal insufficiency, coronary heart disease, bronchial asthma, and other common diseases of older patients. Fifty-five patients (93%) received monotherapy with gemcitabine after the three-drug regimen. The median number of treatment courses received in the monotherapy with gemcitabine was two (range, 0-33 courses).

**Treatment efficacy.** Forty-eight out of 59 patients (81%) had major responses to treatment. The median survival of all patients was 22 months (Fig. 1), and the actuarial 1-year and 2-year survival rates were 68% (19 out of 59 patients died) and 39% (36 out of 59 patients died), respectively. Thirty-three patients (56%) achieved complete responses. After a median follow-up of 17.5 months, 29 patients remained alive and 25 were free of disease progression. The median progression-free survival for the entire group was 10 months (Fig. 2); for patients with objective responses, the median progression-free survival was 14 months (Fig. 3). The median survival time was very different according to the ECOG performance status (Fig. 4): The median survival time for patients with an ECOG status of 0 was 37.5 months, for patients with a status of 1, 17 months, and for patients with a status of 2, 12 months.

**Toxicity.** Neutropenia was the most common grade 3 or 4 toxicity produced by this treatment regimen (Table III). Twenty-three patients (34%) experienced grade 3-4 neutropenia, and 13 patients required hospitalization for the treatment of neutropenia and fever. No case of severe thrombocytopenia and no bleeding episodes were reported.
Severe nonhematological toxicity was uncommon with this treatment regimen. Twenty patients (34%) experienced treatment-related fatigue; emesis was reported in 14 cases (24%). More severe was the treatment-related nausea in 22 cases (37%).

Discussion

This three-drug regimen with a combination of gemcitabine, paclitaxel, and cisplatin was well tolerated and highly effective as a first-line treatment for advanced urothelial carcinoma, as demonstrated by the response rate, the median time to progression and median survival.

Cisplatin-based chemotherapy represents the most effective treatment for advanced urothelial cancer. Nevertheless, the majority of these patients are elderly, have impaired renal function, or have a poor performance status that make them unfit for such treatment. We therefore used the effective three-drug regimen of gemcitabine, paclitaxel and cisplatin with dose modifications for the unfit patients.
In the three reported gemcitabine triplets (36, 41, 42) responses were seen at all sites, including visceral metastases, and the median survival in the cohort of patients with visceral disease was still 14.3, 11.4, and 15.3 months. Table IV shows patient characteristics and the main prognostic factor distributions for these studies in comparison with our results. The overall response rate in the patients with visceral metastases was 77.6% for the cisplatin-based regimen of Bellmunt et al (36), and 68% for the carboplatin-based therapy of Hussain et al (41). Lorusso et al found an overall response rate of only 43% (42). The historical data from the MVAC series showed response rates as low as 20% in patients with visceral disease (10, 12, 43). Also the median survival time for patients who received the PCG-triplet regimen was with 14.3 months compared to that observed with the MVAC series. In our study 81% had major responses to treatment. The median survival of all the patients was very high with 22 months and very close to the median survival time of 24 months from Bellmunt et al (36). Thirty-three patients (56%) achieved complete responses. The median progression-free survival for the entire group was 10 months; for patients with objective responses, the median progression-free survival was 14 months. As it is already known that the ECOG performance status is a predictive factor for survival (44, 47). It is extremely important that these patients are offered effective and not suboptimal chemotherapy (4).

Our treatment was designed on the basis that paired combinations of paclitaxel, gemcitabine and cisplatin, which represent three of the most active single agents in advanced urothelial cancer, and these combinations have been shown to achieve higher response rates than any of the three agents alone. Combination chemotherapy offers the potential to optimise response rates and survival by using agents with complementary mechanisms of action (48).

Besides the development of new chemotherapeutic drug regimes, another approach is the integration of biologically targeted agents into combined modality treatment. Similarly research within molecular biology in bladder cancer may improve our possibilities in selecting patients for different treatment regimes based on new and more specific markers than the ones we have today (49-51).

The addition of paclitaxel to the gemcitabine/cisplatin regimen was found to increase toxicity without any evidence of improved efficacy. Continued clinical analysis of current regimens as well as the development of novel combinations, will be necessary for the continued improvement in the median survival of patients with advanced urothelial carcinoma.

In conclusion, the partial response rate was 81%, and the complete response rate was 56%. The median actuarial survival was 22 months, and the actuarial 1-year and 2-year survival rates were 68% and 39%, respectively. After a median follow-up of 17.5 months, 29 patients remained alive and 25 were free of disease progression. The median progression-free survival for the entire group was 10 months. The combination of gemcitabine, paclitaxel, and cisplatin is a highly effective and tolerable regimen for patients with advanced urothelial carcinoma. This treatment should be considered as a suitable option deserving further prospective evaluation. The ECOG performance status is an important predictive factor for survival.

Acknowledgements
We thank all the involved patients for their participation, and the staff of the Department of Urology and the Institute of

---

**Table IV. Main patient characteristics and prognostic factors of the two gemcitabine containing triplet studies and our results.**

<table>
<thead>
<tr>
<th></th>
<th>Hussain et al (41)</th>
<th>Bellmunt et al (36)</th>
<th>Lorusso et al (42)</th>
<th>Our results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P carbo G study</td>
<td>PCG study</td>
<td>PCG</td>
<td>PCG</td>
</tr>
<tr>
<td>(n=49)</td>
<td></td>
<td>(n=61)</td>
<td>(n=42)</td>
<td>(n=59)</td>
</tr>
<tr>
<td>Median age</td>
<td>63</td>
<td>66</td>
<td>69</td>
<td>70</td>
</tr>
<tr>
<td>ECOG status 0/1/2</td>
<td>24/20/5</td>
<td>21/34/6</td>
<td>18/16/8</td>
<td>24/26/9</td>
</tr>
<tr>
<td>Metastatic %</td>
<td>80</td>
<td>82</td>
<td>76</td>
<td>59</td>
</tr>
<tr>
<td>Visceral metastases %</td>
<td>49</td>
<td>36</td>
<td>55</td>
<td>15</td>
</tr>
<tr>
<td>Overall response (OR) %</td>
<td>68</td>
<td>78</td>
<td>43</td>
<td>81</td>
</tr>
<tr>
<td>Complete response (CR) %</td>
<td>32</td>
<td>28</td>
<td>12</td>
<td>56</td>
</tr>
<tr>
<td>Median survival</td>
<td>14.3</td>
<td>24</td>
<td>15.3</td>
<td>22</td>
</tr>
</tbody>
</table>
Pathology at the Helios Hospital in Bad Saarow for their excellent assistance.

References


